PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

131 articles indexed across 16 specialties, each reviewed by a licensed pharmacist before publication.

⭐ Featured free samples

Three of our best full deep-analysis reports: hand-picked, free to read in full, no subscription required.

🔓 Free Sample
Nephrology / Renal Pharmacy ConfirmatoryGrade: Moderate

Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD

American journal of cardiovascular drugs : drugs, devices, and other interventions · Jul 20, 2026

Finerenone emerges as the safer choice for CKD patients.

Read Free →
🔓 Free Sample
Neurology / Neuropharmacology ConfirmatoryGrade: Low

Tenecteplase Shortens Stroke Treatment and Transfer Times

JAMA network open · Jul 13, 2026

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Free →
🔓 Free Sample
Rheumatology / Immunology ConfirmatoryGrade: Moderate

EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

Annals of the rheumatic diseases · Jun 13, 2026

New EULAR guidelines redefine RA management with DMARDs.

Read Free →
Showing 8 from 1 topic.Sort: Newest | Oldest
Complementary SGLT2 Inhibitor Plus GLP-1 Agonist Therapy in Type 2 Diabetes
Endocrinology / Obesity Confirmatory Grade: Moderate
Porterfield LR, Nadeem S, Swanson D, et al.
📅 Jul 18, 2026 · Current atherosclerosis reports

Combining SGLT2is and GLP-1RAs may revolutionize diabetes management.

PID versus MPC Algorithm Response to Unannounced Meals in Adolescents
Endocrinology / Obesity Hypothesis-generating Grade: Low
Lo Presti D, Scirè Calabrisotto S, Tomaselli LG, et al.
📅 Jul 10, 2026 · Endocrine

The PID algorithm optimizes glycemic control for unannounced meals in adolescents with type 1 diabetes.

ADA Obesity Association Releases 2026 Adult Obesity Diagnosis and Staging Standards
Endocrinology / Obesity Practice-changing Grade: Moderate
American Diabetes Association Professional Practice Committee for Obesity
📅 Jun 4, 2026 · BMJ Open Diabetes Res Care

New obesity guidelines emphasize early screening and tailored diagnosis.

Semaglutide 2.4 mg Improves Liver Histology in MASH
Endocrinology / Obesity Practice-changing Grade: Moderate
Sanyal AJ, Newsome PN, Kliers I, et al.
📅 Apr 30, 2025 · New England Journal of Medicine

Semaglutide shows promise in treating metabolic dysfunction-associated steatohepatitis.

Finerenone Cuts Albuminuria in Type 1 Diabetes with CKD
Endocrinology / Obesity Hypothesis-generating Grade: Moderate
Perkovic V, Tuttle KR, Rossing P, et al.
📅 May 24, 2024 · New England Journal of Medicine

Semaglutide slashes kidney and heart risks in diabetes with kidney disease.

Semaglutide Cuts Cardiovascular Events in Obesity Without Diabetes
Endocrinology / Obesity Practice-changing Grade: High
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
📅 Nov 11, 2023 · New England Journal of Medicine

Semaglutide cuts heart risks in obesity without diabetes.

Semaglutide Cuts Symptoms and Weight in Obesity-Related HFpEF
Endocrinology / Obesity Practice-changing Grade: High
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.
📅 Aug 25, 2023 · New England Journal of Medicine

Semaglutide enhances function and weight loss in obese heart failure patients.

Tirzepatide Delivers Up to 21% Weight Loss in Obesity
Endocrinology / Obesity Practice-changing Grade: High
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
📅 Jun 4, 2022 · New England Journal of Medicine

Tirzepatide delivers unprecedented weight loss results in obesity management.